MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
-0.260
-8.13%
Closed 18:43 05/24 EDT
OPEN
3.110
PREV CLOSE
3.200
HIGH
3.120
LOW
2.920
VOLUME
2.57M
TURNOVER
--
52 WEEK HIGH
35.59
52 WEEK LOW
2.920
MARKET CAP
210.07M
P/E (TTM)
-0.3671
1D
5D
1M
3M
1Y
5Y
Goldman Sachs Adjusts bluebird bio's Price Target to $2 from $3, Keeps Sell Rating
MT Newswires · 22h ago
Roche's Spark Therapeutics, bluebird resolve suit on sickle cell disease 'Spark' campaign
Switzerland's Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and bluebird bio (BLUE) are resolving a trademark infringement litigation related to the Cambridge, Mass.-based gene therapy company's sickle cell disease (SCD) awareness campaign, "Be the Spark," Fierce
Seekingalpha · 5d ago
Bluebird bio stock rises amid price target cut at Morgan Stanley
Bluebird bio (NASDAQ:BLUE) stock rose ~6% on May 17 amid Morgan Stanley lowering its price target on the gene therapy developer's shares to $3 from $5. Morgan Stanley analyst maintained an Underweight
Seekingalpha · 05/17 18:34
Morgan Stanley Adjusts bluebird bio's Price Target to $3 from $5, Keeps Underweight Rating
MT Newswires · 05/17 11:24
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Benzinga · 05/10 18:24
Analyst Ratings for bluebird bio
Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over ...
Benzinga · 05/10 15:05
bluebird bio scales 10% after a massive Y/Y surge in topline figure
bluebird bio (BLUE +10.1%) Q1 shows a revenue beat of $1.78M to $1.95, up +119.1% Y/Y. Research and development expenses from continuing operations were $77.9 million for the three months
Seekingalpha · 05/10 14:58
--Barclays Adjusts bluebird bio's Price Target to $3 from $4, Keeps Underweight Rating
MT Newswires · 05/10 11:56
More
No Data
Learn about the latest financial forecast of BLUE. Analyze the recent business situations of Bluebird Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
76.92%Hold
23.08%Under-perform
0.00%Sell
Analyst Price Target
The average BLUE stock price target is 7.44 with a high estimate of 14.00 and a low estimate of 3.000.
High14.00
Average7.44
Low3.000
Current 2.940
EPS
Actual
Estimate
-2.86-2.15-1.43-0.72
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 337
Institutional Holdings: 60.91M
% Owned: 85.25%
Shares Outstanding: 71.45M
TypeInstitutionsShares
Increased
61
10.01M
New
27
1.03M
Decreased
46
3.27M
Sold Out
44
1.69M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
President/Chief Executive Officer/Director
Andrew Obenshain
Chief Financial Officer/Treasurer
Jason Cole
Chief Accounting Officer
Jessica Whitten
Other
Thomas Klima
Director
Charlotte Jones-Burton
Director
Elisabeth Leiderman
Director
Najoh Tita-reid
Independent Director
John Agwunobi
Independent Director
Mark Vachon
No Data
No Data
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.